JP2018537536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537536A5 JP2018537536A5 JP2018549407A JP2018549407A JP2018537536A5 JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5 JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- cells
- composition according
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265382P | 2015-12-09 | 2015-12-09 | |
| US62/265,382 | 2015-12-09 | ||
| PCT/US2016/066018 WO2017100709A1 (en) | 2015-12-09 | 2016-12-09 | Compositions and methods for treatment of her2 positive metastatic breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537536A JP2018537536A (ja) | 2018-12-20 |
| JP2018537536A5 true JP2018537536A5 (enExample) | 2019-12-12 |
Family
ID=59013368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549407A Pending JP2018537536A (ja) | 2015-12-09 | 2016-12-09 | Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180360881A1 (enExample) |
| EP (1) | EP3386522A4 (enExample) |
| JP (1) | JP2018537536A (enExample) |
| KR (1) | KR20180123214A (enExample) |
| CN (1) | CN109475576A (enExample) |
| AU (1) | AU2016366677A1 (enExample) |
| CA (1) | CA3007996A1 (enExample) |
| WO (1) | WO2017100709A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| EP3641890A4 (en) * | 2017-06-22 | 2021-01-13 | University of Southern California | ANTI-CANCER POLYTHERAPY USING MANIPULATED NATURAL KILLER CELLS WITH CHEMERIC ANTIGENIC RECEPTOR AS CHEMOTHERAPEUTIC DRUG CARRIERS |
| KR20220068272A (ko) | 2017-08-15 | 2022-05-25 | 난트셀, 인크. | Hank 세툭시맙 조합 및 방법 |
| CN110484507B (zh) * | 2018-01-31 | 2023-10-13 | 温州医科大学 | 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术 |
| IL321548A (en) * | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| TW202019487A (zh) | 2018-08-06 | 2020-06-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物及微管蛋白抑制劑之組合 |
| US11077143B2 (en) * | 2018-10-31 | 2021-08-03 | Nantkwest Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
| CA3148608A1 (en) * | 2019-07-26 | 2021-02-04 | Immunitybio, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN112675313A (zh) * | 2020-12-28 | 2021-04-20 | 烟台大学 | 连接曲妥珠单抗片段的美登素纳米粒组合物 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1485127T1 (sl) * | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| ES2374603T3 (es) * | 2005-01-06 | 2012-02-20 | Novo Nordisk A/S | Agentes de unión a kir y procedimientos de uso de los mismos. |
| ES2707152T3 (es) * | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| EP3701957B1 (en) * | 2013-11-01 | 2022-12-28 | ImmunityBio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| EP3122769B1 (en) * | 2014-03-28 | 2023-02-22 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
| CN107613993A (zh) * | 2015-03-27 | 2018-01-19 | 南克维斯特公司 | 与癌症药物的联合治疗中的nk‑92细胞 |
-
2016
- 2016-12-09 EP EP16874010.8A patent/EP3386522A4/en not_active Withdrawn
- 2016-12-09 JP JP2018549407A patent/JP2018537536A/ja active Pending
- 2016-12-09 US US15/781,428 patent/US20180360881A1/en not_active Abandoned
- 2016-12-09 CA CA3007996A patent/CA3007996A1/en active Pending
- 2016-12-09 WO PCT/US2016/066018 patent/WO2017100709A1/en not_active Ceased
- 2016-12-09 KR KR1020187019391A patent/KR20180123214A/ko not_active Ceased
- 2016-12-09 AU AU2016366677A patent/AU2016366677A1/en not_active Abandoned
- 2016-12-09 CN CN201680080518.8A patent/CN109475576A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Herrera et al. | Bispecific antibodies: advancing precision oncology | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Vacchelli et al. | Trial watch: Monoclonal antibodies in cancer therapy | |
| Dees et al. | Bispecific antibodies for triple negative breast cancer | |
| Shabaneh et al. | Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| JP2019513777A5 (enExample) | ||
| Albayrak et al. | T cell engagers: expanding horizons in oncology and beyond: Translational Therapeutics | |
| Vyas et al. | Antigen loss variants: catching hold of escaping foes | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| CN111886015B (zh) | 用于同种异体嵌合抗原受体t细胞的给药的方法和组合物 | |
| JP2017507936A5 (enExample) | ||
| Attarwala | Role of antibodies in cancer targeting | |
| Patriarca et al. | Investigational drugs for the treatment of diffuse large B-cell lymphoma | |
| JP2018529327A5 (enExample) | ||
| Kamakura et al. | T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity | |
| JP2016187356A5 (enExample) | ||
| JP2016513458A5 (enExample) | ||
| JP2015517470A5 (enExample) | ||
| Saini et al. | Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment | |
| Pulido et al. | Hopes on immunotherapy targeting B7-H3 in neuroblastoma | |
| Mao et al. | Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours |